Effect of Curcumin on Gut Microbiota in IBS
Launched by MEDICAL COLLEGE OF WISCONSIN · Jun 15, 2018
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
This is a prospective, placebo-controlled, double blinded, randomized control trial. This study will evaluate the effect of curcumin food supplement on gut microbiota of children with irritable bowel syndrome. Curcumin is a commonly used spice in Asian cooking and has a very good safety profile. Developing preparation of this compound for targeted delivery in the GI tract would provide a novel way to treat common FGID. This study will provide preliminary data for future studies to evaluate the role of gut microbiota in the pathophysiology of pain predominant FGID and how food supplements ca...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 10 to 18 years old
- • Fulfill the Rome IV criteria for diarrhea predominant IBS
- • English speaking
- • Able to swallow curcumin/placebo capsules
- Exclusion Criteria:
- • Weigh less than 35 kg
- • On any form of dietary restrictions
- • Taken probiotics one month before enrollment
- • Antibiotic treatment one month before enrollment
- • IBD
- • Celiac disease
- • Peptic ulcer disease
- • H. Pylori gastritis
- • Abnormality of gastrointestinal tract
- • Previous abnormal endoscope
- • Previous abdominal surgeries
- • Gall stones
- • Biliary tract obstructions
- • Liver pathologies
- • Liver failure
- • Active GI infection
- • Positive stool cultures
- • Drug or alcohol abuse
- • Concomitant immunological/hematological/neoplastic/heart/ renal/pulmonary condition
- • Any other medical condition or taking any form of drug(s) which can explain the current symptoms
- • Take oral or intravenous drugs which could have potential drug interaction with curcumin
- • Lactating or pregnant or planning to become pregnant
- • Developmental delay
- • Parents that are developmentally delayed
- • Have a diet high in curcumin/turmeric
About Medical College Of Wisconsin
The Medical College of Wisconsin (MCW) is a leading academic institution dedicated to advancing healthcare through innovative research, education, and clinical practice. As a prominent clinical trial sponsor, MCW is committed to conducting high-quality, ethically-guided research that aims to improve patient outcomes and address critical health challenges. Leveraging a multidisciplinary approach, MCW collaborates with a diverse network of healthcare professionals, researchers, and community partners to facilitate groundbreaking clinical trials across various medical fields, ensuring the translation of scientific discoveries into effective treatments and practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milwaukee, Wisconsin, United States
Patients applied
Trial Officials
Manu Sood, MD
Principal Investigator
Medical College of Wisconsin
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials